Cost-Benefit Analysis Comparing Trough, Two-Level AUC, and Bayesian AUC Dosing for Vancomycin': Authors' Reply
Response or Comment
"Our response to your letter will address the two primary concerns in sequential order: the first concern being the Bayesian AUC to trough comparison, and the second being two-level AUC to trough."
Lee BV, Fong G, Bolaris M, et al. 'Cost-benefit analysis comparing trough, two-level AUC, and Bayesian AUC dosing for vancomycin': authors' reply. Clin Microbiol Infect. 2021;27(6):929-930. https://doi.org/10.1016/j.cmi.2021.01.015
This article was originally published in Clinical Microbiology and Infection, volume 27, issue 6, in 2021. https://doi.org/10.1016/j.cmi.2021.01.015